- 5.2Impact Factor
- 10.5CiteScore
- 16 daysTime to First Decision
Advances in Molecular Research on Cancer Drug Targets and Drug Resistance
Special Issue Information
Dear Colleagues,
Cancer remains a formidable global health challenge, necessitating continuous innovation in therapeutic strategies. Significant advancements in treatment have emerged from a deeper molecular understanding of cancer biology, leading to the identification of specific drug targets and the development of targeted therapies. However, despite these successes, the challenge of drug resistance frequently limits treatment efficacy and contributes to disease recurrence. This underscores the critical need for ongoing molecular research to not only discover novel targets but also to overcome the complex mechanisms by which cancer cells evade therapeutic agents.
Therefore, this Special Issue aims to compile cutting-edge original research and comprehensive review articles that advance our understanding of the molecular basis of cancer drug targets and the mechanisms of drug resistance. Our objective is to gather a comprehensive collection of at least 10 articles, with the potential for the Special Issue to be printed in book form if this number is achieved.
In this Special Issue, research areas may include the discovery and validation of novel molecular targets, elucidation of molecular mechanisms of intrinsic and acquired drug resistance, the role of tumor heterogeneity and the tumor microenvironment in resistance, strategies to overcome resistance, development of biomarkers for predicting response and resistance, and studies on new anti-cancer agents and resistance modulators.
We look forward to receiving your contributions.
Dr. Yuhao Xie
Prof. Dr. Concettina La Motta
Dr. Rakesh Kumar Srivastava
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- drug targets
- drug resistance
- molecular mechanisms
- targeted therapy
- tumor microenvironment
- personalized medicine
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

